Dennis Ding
Stock Analyst at Jefferies
(2.29)
# 2,688
Out of 5,241 analysts
15
Total ratings
36.36%
Success rate
16.01%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMPH Amphastar Pharmaceuticals | Downgrades: Hold | $30 → $22 | $17.20 | +27.91% | 1 | Apr 21, 2026 | |
| OLMA Olema Pharmaceuticals | Assumes: Buy | $43 → $40 | $12.90 | +210.08% | 1 | Mar 19, 2026 | |
| SGP SpyGlass Pharma | Initiates: Buy | $62 | $22.27 | +178.40% | 1 | Mar 3, 2026 | |
| ROIV Roivant Sciences | Maintains: Buy | $18 → $20 | $28.55 | -29.95% | 2 | Sep 18, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Hold | $15 → $26 | $26.39 | -1.48% | 2 | Sep 3, 2025 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $55 | $34.70 | +58.50% | 1 | Jan 22, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $1.61 | +396.89% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $27.42 | +27.64% | 1 | Sep 20, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $4.17 | +67.87% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $2.89 | +107.61% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $35 → $22 | $55.12 | -60.09% | 1 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $34.14 | -29.70% | 1 | Dec 19, 2022 |
Amphastar Pharmaceuticals
Apr 21, 2026
Downgrades: Hold
Price Target: $30 → $22
Current: $17.20
Upside: +27.91%
Olema Pharmaceuticals
Mar 19, 2026
Assumes: Buy
Price Target: $43 → $40
Current: $12.90
Upside: +210.08%
SpyGlass Pharma
Mar 3, 2026
Initiates: Buy
Price Target: $62
Current: $22.27
Upside: +178.40%
Roivant Sciences
Sep 18, 2025
Maintains: Buy
Price Target: $18 → $20
Current: $28.55
Upside: -29.95%
Mineralys Therapeutics
Sep 3, 2025
Maintains: Hold
Price Target: $15 → $26
Current: $26.39
Upside: -1.48%
Crinetics Pharmaceuticals
Jan 22, 2025
Upgrades: Buy
Price Target: $55
Current: $34.70
Upside: +58.50%
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $1.61
Upside: +396.89%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $27.42
Upside: +27.64%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $4.17
Upside: +67.87%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $2.89
Upside: +107.61%
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $55.12
Upside: -60.09%
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $34.14
Upside: -29.70%